Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1
نویسندگان
چکیده
منابع مشابه
Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1.
We retrospectively analyzed the efficacy of chemotherapy in patients whose gastric cancer recurred after adjuvant chemotherapy with S-1. A total of 51 patients were evaluated. Twenty-one patients received S-1-containing chemotherapy as first-line treatment after recurrence [cohort A: S-1 plus cisplatin (n = 10), S-1 monotherapy (n = 7), S-1 plus irinotecan (n = 3) and S-1 plus docetaxel (n = 1)...
متن کاملAdjuvant S-1 chemotherapy after curative resection of gastric cancer.
To the Editor—In the February issue of Hong Kong Medical Journal, Yeo et al1 reported an informative study on the use of S-1 as adjunct chemotherapy after curative resection of gastric cancer. Since the active ingredient in S-1 is the prodrug tegafur, to be converted to 5-fluorouracil (5FU), much of the toxicity reduction depends on the degradation of 5FU by dihydropyrimidine dehydrogenase (DPD...
متن کاملRelapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
S-1 has been recommended as adjuvant chemotherapy in patients after curative surgery for gastric cancer. However, some patients suffer recurrence even after S-1 adjuvant chemotherapy. The present study was conducted to find a predictive marker of the efficacy of S-1 adjuvant chemotherapy. We examined the microRNA (miRNA) expression of 35 patients who underwent S-1 adjuvant chemotherapy after cu...
متن کاملDose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.
Gastric cancer (GC) is the fourth most common type of cancer, accounting for an estimated one million new cases annually worldwide. Locally advanced GC often recurs, even following curative surgical resection. Therefore, there is a need for an effective adjuvant chemotherapy regimen. The aim of this trial was to investigate the maximum tolerated dose (MTD) of S-1 when administered in combinatio...
متن کاملAdjuvant chemotherapy for chemotherapy-naive advanced gastric cancer patients with oxaliplatin plus tegafur versus oxaliplatin plus S-1
Background: Advanced gastric cancer (AGC) causes a huge economic burden to the society. This openlabel study was conducted to compare the efficacy and acceptability of oxaliplatin plus tegafur (OXT) vs. oxaliplatin plus S-1 (OXS) for chemotherapy-naive advanced gastric cancer patients. Material and methods: In this study, patients were randomly assigned to receive OXT or OXS. In a 3-week treatm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Oncology
سال: 2008
ISSN: 0368-2811,1465-3621
DOI: 10.1093/jjco/hyn096